Brief: Idera Announces Preliminary Data From Illuminate-206 Trial For Treatment Of Micro-Satellite Stable Colorectal Cancer

Aceragen

02/06/2020 13:53

June 2 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM AND
PLANNED CONTINUATION OF THE ILLUMINATE-206 TRIAL FOR THE
TREATMENT OF MICRO-SATELLITE STABLE COLORECTAL CANCER
    * IDERA PHARMACEUTICALS - BASED ON DATA TO DATE, PLANS TO
EXPAND
STUDY TO FURTHER EVALUATE TRIPLET COMBINATION IN MSS-CRC
    * IDERA PHARMACEUTICALS - ILLUMINATE-206 REGIMEN WAS
GENERALLY
WELL TOLERATED
    * IDERA PHARMACEUTICALS - NO PATIENTS DISCONTINUED TREATMENT
DUE
TO ADVERSE EVENTS & NONE EXPERIENCED GRADE 4 OR 5 AES IN
ILLUMINATE-206 TRIAL
    * IDERA PHARMACEUTICALS - ENROLLMENT OF NEXT 10 PATIENTS IS
TARGETED TO BEGIN IN Q4 OF 2020, WITH DATA ANTICIPATED IN Q2 OF
2021

Source text for Eikon:  ID:nGNX1vTkJy 
Further company coverage:  IDRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))